Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Blizzards and user fees

This article was originally published in The Gray Sheet

Executive Summary

FDA said it will extend congressionally-mandated decision deadlines for devices and drugs whose Medical Device User Fee Act (MDUFA) or Prescription Drug User Fee Act (PDUFA) decision goals came due during or shortly after the extreme winter storms that swept through Washington, D.C., and shut down FDA offices earlier this month. FDA is extending the deadline for user fee decisions due the weeks of Feb. 8 and Feb. 15 by up to four business days for devices and five business days for drugs. Further, product submissions that would normally have been received during the closure will not be marked as "received," for purposes of starting the regulatory clock, until the FDA center resumes normal operations

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel